J
Jan O. Aasly
Researcher at Norwegian University of Science and Technology
Publications - 193
Citations - 16161
Jan O. Aasly is an academic researcher from Norwegian University of Science and Technology. The author has contributed to research in topics: Parkinson's disease & LRRK2. The author has an hindex of 53, co-authored 175 publications receiving 14369 citations. Previous affiliations of Jan O. Aasly include University of British Columbia.
Papers
More filters
Journal ArticleDOI
Genetically-controlled Vesicle-Associated Membrane Protein 1 expression may contribute to Alzheimer’s pathophysiology and susceptibility
Daniel Sevlever,Fanggeng Zou,Fanggeng Zou,Li Ma,Sebastian Carrasquillo,Michael Crump,Oliver J. Culley,Talisha A. Hunter,Gina Bisceglio,Linda H. Younkin,Mariet Allen,Minerva M. Carrasquillo,Sigrid Botne Sando,Jan O. Aasly,Dennis W. Dickson,Neill R. Graff-Radford,Ronald C. Petersen,Ferenc Deak,Ferenc Deak,Olivia Belbin,Olivia Belbin +20 more
TL;DR: Genetically regulated VAMP1 expression in the brain may modify both Alzheimer’s disease risk and may contribute to Alzheimer's pathophysiology.
Journal ArticleDOI
Alpha-synuclein repeat variants and survival in Parkinson's disease.
Sun Ju Chung,Joanna M. Biernacka,Sebastian M. Armasu,Kari J. Anderson,Roberta Frigerio,Jan O. Aasly,Grazia Annesi,Anna Rita Bentivoglio,Laura Brighina,Marie-Christine Chartier-Harlin,Marie-Christine Chartier-Harlin,Stefano Goldwurm,Georgios M. Hadjigeorgiou,Barbara Jasinska-Myga,Beom S. Jeon,Yun Joong Kim,Rejko Krüger,Suzanne Lesage,Katerina Markopoulou,George D. Mellick,Karen E. Morrison,Andreas Puschmann,Eng-King Tan,David Crosiers,Jessie Theuns,Christine Van Broeckhoven,Karin Wirdefeldt,Zbigniew K. Wszolek,Alexis Elbaz,Demetrius M. Maraganore +29 more
TL;DR: To determine whether α‐synuclein dinucleotide repeat (REP1) genotypes are associated with survival in Parkinson's disease (PD), a genome-wide association study is conducted with real-time radiolysis data to establish a probabilistic association betweenREP1 and PD.
Journal ArticleDOI
Progressive Multifocal Leukoencephalopathy in an Immunocompetent Patient
TL;DR: PML should be considered in patients with progressive neurological disorders involving the white matter, even in the absence of previous immunomodulatory treatment or immunosuppression, according to a 72-year-old previously healthy woman.
Journal ArticleDOI
Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study
C. Domenighetti,Pierre-Emmanuel Sugier,Ashwin Ashok Kumar Sreelatha,Claudia Schulte,Sandeep Grover,Oceane Mohamed,Berta Portugal,Patrick May,Dheeraj Reddy Bobbili,Milena Radivojkov-Blagojevic,Peter Lichter,Andrew B. Singleton,Dena G. Hernandez,Connor Edsall,George D. Mellick,Alexander Zimprich,Walter Pirker,Ekaterina Rogaeva,Anthony E. Lang,Sulev Kõks,Pille Taba,Suzanne Lesage,Alexis Brice,Jean-Christophe Corvol,Marie-Christine Chartier-Harlin,Eugénie Mutez,Kathrin Brockmann,Angela Deutschländer,Georgios M. Hadjigeorgiou,Efthimios Dardiotis,Leonidas Stefanis,Athina Simitsi,Enza Maria Valente,Simona Petrucci,Stefano Duga,Letizia Straniero,Anna Zecchinelli,Gianni Pezzoli,Laura Brighina,Carlo Ferrarese,Grazia Annesi,A. Quattrone,Monica Gagliardi,Hirotaka Matsuo,Yusuke Kawamura,Nobutaka Hattori,Kenya Nishioka,Sun Ju Chung,Yun Joong Kim,Pierre Kolber,Bart P.C. van de Warrenburg,Bastiaan R. Bloem,Jan O. Aasly,Mathias Toft,Lasse Pihlstrøm,Leonor Correia Guedes,Joaquim J. Ferreira,Soraya Bardien,Jonathan Carr,Eduardo Tolosa,Mario Ezquerra,Pau Pastor,Monica Diez-Fairen,Karin Wirdefeldt,Nancy L. Pedersen,Caroline Ran,Andrea Carmine Belin,Andreas Puschmann,Clara Hellberg,Carl E Clarke,Karen E. Morrison,Manuela Tan,Dimitri Krainc,Lena F. Burbulla,Matthew J. Farrer,Rejko Krüger,Thomas Gasser,Manu Sharma,Alexis Elbaz +78 more
TL;DR: In this article , the authors highlighted dairy intake as a risk factor for Parkinson's disease (PD), particularly in men, but it is unclear whether this association is causal or explained by reverse causation or confounding.
Journal ArticleDOI
Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage
Nour K. Majbour,Jan O. Aasly,Ilham Y Abdi,Simona S. Ghanem,Daniel Erskine,W. D. J. van de Berg,Omar M. A. El-Agnaf +6 more
TL;DR: It is shown that combining SAA and ELISA assays is more promising diagnostic tool than SAA alone, providing information about the disease stage by correlating with clinical measures of disease severity.